{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:11:56Z","timestamp":1792552316127,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T00:00:00Z","timestamp":1512432000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s40265-017-0852-8","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T07:37:01Z","timestamp":1512459421000},"page":"139-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Acalabrutinib: First Global Approval"],"prefix":"10.1007","volume":"78","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohita","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,5]]},"reference":[{"key":"852_CR1","unstructured":"AstraZeneca, Acerta Pharma. Acalabrutinib granted breakthrough therapy designation by US FDA for the treatment of patients with mantle cell lymphoma [media release]. 1 Aug 2017. http:\/\/www.acerta-pharma.com ."},{"key":"852_CR2","unstructured":"FDA. FDA approves new treatment for adults with mantle cell lymphoma [media release]. 31 Oct 2017. https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm583076.htm ."},{"key":"852_CR3","unstructured":"Acerta Pharma. Acerta Pharma announces strategic transaction with AstraZeneca [media release]. 17 Dec 2015. http:\/\/www.acerta-pharma.com ."},{"issue":"23","key":"852_CR4","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V126.23.2908.2908","volume":"126","author":"BK Harrington","year":"2015","unstructured":"Harrington BK, Gulrajani M, Covey T, et al. ACP-196 is a second generation inhibitor of bruton tyrosine kinase (BTK) with enhanced target specificity [abstract]. Blood. 2015;126(23):2908.","journal-title":"Blood."},{"key":"852_CR5","doi-asserted-by":"crossref","unstructured":"Covey T, Barf T, Gulrajani M, et al. ACP-196: a novel covalent Bruton\u2019s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients [abstract no. 2596]. Cancer Res. 2015;75(15 Suppl).","DOI":"10.1158\/1538-7445.AM2015-2596"},{"issue":"4","key":"852_CR6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC, Harrington B, O\u2019Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323\u201332.","journal-title":"N Engl J Med."},{"issue":"11","key":"852_CR7","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","volume":"23","author":"SEM Herman","year":"2017","unstructured":"Herman SEM, Montraveta A, Niemann CU, et al. The Bruton Tyrosine Kinase (BTK) inhibitor acalabrutinib demonstrates potent on-target effects and efficacy in two mouse models of chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(11):2831\u201341.","journal-title":"Clin Cancer Res."},{"issue":"7","key":"852_CR8","doi-asserted-by":"crossref","first-page":"e0159607","DOI":"10.1371\/journal.pone.0159607","volume":"11","author":"BK Harrington","year":"2016","unstructured":"Harrington BK, Gardner HL, Izumi R, et al. Preclinical evaluation of the novel BTK inhibitor acalabrutinib in canine models of B-cell non-Hodgkin lymphoma. PLoS ONE. 2016;11(7):e0159607.","journal-title":"PLoS ONE."},{"key":"852_CR9","unstructured":"AstraZeneca. CALQUENCE\u00ae (acalabrutinib): prescribing information. 2017. https:\/\/www.azpicentral.com\/calquence\/calquence.pdf#page=1 . Accessed 2017."},{"key":"852_CR10","unstructured":"Wang M, Rule SA, Zinzani PL, et al. Efficacy and safety of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma in the phase 2 ACE-LY-004 study [abstract no. 155]. In: American Society of Hematology (ASH) 59th Annual Meeting and Exposition. 2017."},{"issue":"22","key":"852_CR11","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood.V128.22.638.638","volume":"128","author":"FT Awan","year":"2016","unstructured":"Awan FT, Schuh A, Brown JR, et al. Acalabrutinib monotherapy in patients with ibrutinib intolerance: results from the phase 1\/2 ACE-CL-001 clinical study [abstract]. Blood. 2016;128(22):638.","journal-title":"Blood."},{"issue":"22","key":"852_CR12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood.V128.22.60.60","volume":"128","author":"P Hillmen","year":"2016","unstructured":"Hillmen P, Schuh A, Eyre TA, et al. Acalabrutinib monotherapy in patients with richter transformation from the phase 1\/2 ACE-CL-001 clinical study [abstract]. Blood. 2016;128(22):60.","journal-title":"Blood."},{"key":"852_CR13","unstructured":"Byrd J, Wierda W, Schuh A, et al. Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated results from the phase 1\/2 ACE-CL-001 study [abstract no. 498]. In: American Society of Hematology (ASH) 59th Annual Meeting and Exposition. 2017."},{"issue":"Suppl 1","key":"852_CR14","first-page":"151","volume":"101","author":"W Wierda","year":"2016","unstructured":"Wierda W, Jones J, Furman R, et al. Acalabrutinib, a second-generation bruton tyrosine kinase (BTK) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL) [abstract no. S431]. Haematologica. 2016;101(Suppl 1):151.","journal-title":"Haematologica."},{"key":"852_CR15","unstructured":"Woyach J, Awan F, Jianfar M, et al. Acalabrutinib with obinutuzumab in relapsed\/refractory and treatment-naive patients with chronic lymphocytic leukemia: the phase 1b\/2 ACE-CL-003 study [abstract no. 432]. In: American Society of Hematology (ASH) 59th Annual Meeting and Exposition. 2017."},{"key":"852_CR16","doi-asserted-by":"crossref","unstructured":"Overman MJ, Lopez CD, Benson AB, et al. A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC) [abstract no. 4130]. J Clin Oncol. 2016;34(15 Suppl).","DOI":"10.1200\/JCO.2016.34.15_suppl.4130"},{"issue":"Suppl 5","key":"852_CR17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/annonc\/mdx371.017","volume":"28","author":"T Zhang","year":"2017","unstructured":"Zhang T, Harrison M, O\u2019Donnell P, et al. Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC) [abstract no. 863P]. Ann Oncol. 2017;28(Suppl 5):303\u20134.","journal-title":"Ann Oncol."},{"key":"852_CR18","unstructured":"Byrd J, Owen R, O\u2019Brien S, et al. Pooled Analysis of Safety Data from Clinical Trials Evaluating Acalabrutinib Monotherapy in Hematologic Malignancies [abstract no. 4326]. In: American Society of Hematology (ASH) 59th Annual Meeting and Exposition. 2017."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0852-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0852-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0852-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T16:16:39Z","timestamp":1603469799000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0852-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,5]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0852-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,5]]}}}